Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Obseva S.A.
Headquarters: Geneva, Switzerland
Website: N/A
Year Founded: 2012
Status: Out of Business
BioCentury | Sep 15, 2023
Management Tracks
O’Callaghan to lead Deep Genomics as CEO
Plus: Pliant hires Kuo and updates for Helsinn Group, Sling, Repairon, Nusano and Fractyl
BioCentury | May 3, 2023
Management Tracks
Filius to depart Galapagos
Plus: Modis joins Amphista as CSO and updates from ObsEva, CS Genetics, Resolution and Newron
BioCentury | Feb 25, 2023
Deals
Feb. 24 Quick Takes: Novartis returns NASH program’s rights to Pliant
Plus: ObsEva, EQRx downsize and updates from Olatec, Pfizer
BioCentury | Nov 10, 2022
Data Byte
Drug development for preterm birth still largely a no-fly zone
Of five disclosed programs to prevent preterm birth, three are preclinical while one clinical program was recently deprioritized
BioCentury | Sep 3, 2022
Data Byte
At least 8 PDUFA dates on deck in September
Three submissions are under FDA priority review
BioCentury | Jul 28, 2022
Regulation
July 27 Quick Takes: Cidara, Melinta in deal for antifungal headed to FDA
Plus Legend gains after upsizing financing and updates from Lexicon, ObsEva, Cassava, Legend and more
BioCentury | May 20, 2022
Management Tracks
Schoenfeld becomes Mark Foundation CEO
Plus new CDO at iosBio, and updates from Cerebral, Helsinn, CureDuchenne and more
BioCentury | May 3, 2022
Management Tracks
Jansen to retire from Pfizer
Plus Patel leaves FDA and updates from Roivant, Aldeyra, Omega and more
BioCentury | Feb 8, 2022
Finance
Feb. 7 Quick Takes: WuXi Biologics shares fall after landing on Commerce list
Plus mega-rounds for Endeavor, Dewpoint and updates from Koneksa, ObsEva and more
BioCentury | Feb 2, 2022
Management Tracks
Roche’s William Pao joins Pfizer as CDO
Plus Clevers succeeds Pao at Roche, new CEO, CFO and other changes at Sosei and updates from Biomea, BeiGene, Cortexyme and more
Items per page:
1 - 10 of 67